Replies to post #150 on Ventana Biotech, Inc. (VNTA)

[sam1933]

Behind the Scenes at the Ventana/Prime BioResearch collaboration

RELEASE – NOV 08
http://www.primebioresearch.com/prime_pressrelease_nov08.pdf

FOR IMMEDIATE RELEASE
Prime BioResearch in Mergers and Acquisitions Negotiations
London, (DATE) – Prime BioResearch Ltd, (“PBR” or “the Company”) a target-drug acquisition and development company, is pleased to announce that it has entered into exciting negotiations with potential partners in the United States.

In recent weeks, the Company has been approached by numerous companies who have expressed interest in PBR’s business model and Intellectual Property assets, which include promising drug targets for Type 2 Diabetes and Obesity.

At the same time, PBR’s management has been actively seeking new acquisition targets in various stages of development. Given the current world financial situation, management has found itself in an opportune position with access to exciting developmental drugs at bargain prices.

PBR CEO Erling Refsum says, “We are currently involved in exciting merger and acquisitions deals that could lead to big changes for the company and promising news for our shareholders.” Furthermore, the Company is involved in a hiring process for new additions to its management team, which presently consists of a world-class group of medical and financial experts.

The Company will release official statements in regards to its deals in development and management team changes by Christmas this year.

About Prime BioResearch PBR is in the business of identifying, evaluating and acquiring potential blockbuster developmental drugs in medical markets with significant growth potential.
It focuses on developing primary care drugs for the prevention and treatment of metabolic disorders (Obesity and Type 2 Diabetes), inflammatory diseases (arthritis, bowel diseases) and
cardiovascular diseases.
The Company leverages early partnerships to share costs and research results, and then out-licenses the drugs for further development. PBR therefore operates within the prime spot of value creation between small academic groups with outstanding research, and the big pharmaceutical companies.

PBR currently has a proprietary portfolio of six worldwide patents in Obesity and Diabetes-II with potential value of $2.9 billion, if successfully brought through development, clinical trials, and to market, according to major accounting advisers. The Company’s mission is to make safe and effective drugs available to the public, quickly and at affordable levels.

For more information about Prime BioResearch Ltd, please contact:
[phone] or [e-mail]